NCT05662020 2022-12-27
A Study to Evaluate the Immunogenicity and Safety of HPV Vaccine in Healthy Female Participants Aged 9-26 Years in China
Beijing Health Guard Biotechnology, Inc
Phase 3 Active not recruiting
Clinical Trials
7 trialsNCT01735006 2020-02-24
Efficacy and Immunogenicity Study of Recombinant Human Papillomavirus Bivalent（Type 16/18 ）Vaccine
Xiamen University
Phase 3 Completed
NCT00578227 2018-08-17
Evaluation of Safety and Immunogenicity of Co-administering Human Papillomavirus Vaccine With Another Vaccine in Healthy Female Subjects
GlaxoSmithKline
Phase 3 Completed
NCT00652938 2018-08-17
Evaluation of Immunogenicity and Safety of Human Papillomavirus (HPV) Vaccine Co-administered With Another Vaccine in Healthy Female Subjects
GlaxoSmithKline
Phase 3 Completed
NCT00552279 2018-06-25
Immunogenicity and Safety of GlaxoSmithKline Biologicals' Huma Papillomavirus (HPV) Vaccine 580299 in Healthy Females 15 - 25 Years of Age
GlaxoSmithKline
Phase 3 Completed
NCT00092521 2015-09-25
Cervical Intraepithelial Neoplasm (CIN)-Warts Efficacy Trial in Women (Gardasil)(V501-013)(COMPLETED)
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT00501137 2015-04-10
BCGov-01
University of British Columbia
Phase 3 Completed